{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:58:09Z","timestamp":1790927889210,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:00:00Z","timestamp":1783209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T00:00:00Z","timestamp":1783209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinical outcomes of mpox (clade IIb) among people living with HIV (PWH) require clarification, particularly the role of immune status in determining disease severity. This multicentre study assessed differences in mpox clinical outcomes and hospitalization between PWH and PrEP users across European clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Individuals with PCR\u2010confirmed mpox attending sexual health\/HIV and infectious diseases services in 11 European countries between May 2022\u2013December 2023 were included. Comparisons between PWH versus PrEP users were made using Chi\u2010square tests for categorical variables and\n                      <jats:italic>t<\/jats:italic>\n                      \u2010tests for continuous variables; adjusted analyses accounting for study site used mixed\u2010effects logistic and Cox regression models. Univariable and multivariable models assessed key predictors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The proportion of clinic attendees with mpox ranged from 0.34%\u20133.07% across sites (946 PWH, 1054 PrEP users). Overall, 745\/1989 (37%) individuals experienced at least one mpox\u2010related clinical complication. Median time to lesion resolution was 18\u2009days (IQR 13\u201323). No deaths occurred. In unadjusted analysis, hospitalization was more frequent among PWH (57\/946, 6% vs. 38\/1054, 4%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.011), but this difference was not significant after site\u2010adjustment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.389). Despite low numbers, among PWH with recent CD4 measurements, CD4\u2009&lt;\u2009200\/mm\n                      <jats:sup>3<\/jats:sup>\n                      was associated with significantly increased hospitalization (36% vs. 4%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003). Immunosuppression was linked to hospitalization (aOR 3.00, 95% CI 1.03\u20138.78).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mpox clinical outcomes were generally favourable in both PWH and PrEP users with adequate immune function. Severe immunosuppression, rather than HIV status per se, was associated with hospitalization risk. These findings support prioritized clinical monitoring for individuals with advanced immunodeficiency and highlight the importance of immune status assessment in mpox management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70283","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:58:02Z","timestamp":1783299482000},"page":"1617-1628","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mpox clinical outcomes among people living with HIV and PrEP users: Findings from the MASH\u20101 multicentre cohort study"],"prefix":"10.1111","volume":"27","author":[{"given":"Nicolo","family":"Girometti","sequence":"first","affiliation":[{"name":"Chelsea and Westminster Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hill","sequence":"additional","affiliation":[{"name":"Metavirology Ltd  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3207-9935","authenticated-orcid":false,"given":"Bryony","family":"Simmons","sequence":"additional","affiliation":[{"name":"Metavirology Ltd  London UK"},{"name":"LSE Health, London School of Economics and Political Science  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Byrne","sequence":"additional","affiliation":[{"name":"Chelsea and Westminster Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Blanco","sequence":"additional","affiliation":[{"name":"Hospital Clinic de Barcelona  Barcelona Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Estrada","sequence":"additional","affiliation":[{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III  Madrid Spain"},{"name":"Hospital Clinico San Carlos  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Assistance Publique \u2013 H\u00f4pitaux de Paris.Nord, H\u00f4pital Bichat, Service des Maladies Infectieuses  Paris France"},{"name":"Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1137 IAME  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Curran","sequence":"additional","affiliation":[{"name":"Hospital Universitari Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Kowalska","sequence":"additional","affiliation":[{"name":"Euroguidelines in Central and Eastern Europe Network Group  Warsaw Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Sobande","sequence":"additional","affiliation":[{"name":"Research Organisation Kings Cross  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6911-8846","authenticated-orcid":false,"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[{"name":"Hospital Clinic de Barcelona  Barcelona Spain"},{"name":"CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III  Madrid Spain"},{"name":"Reial Acad\u00e8mia de Medicina de Catalunya  Barcelona Spain"},{"name":"NEAT ID  Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the MASH\u20101 study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,5]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"WHO.Mpox outbreak: global trends.2022\u20102024. Accessed January 26 2026.https:\/\/worldhealthorg.shinyapps.io\/mpx_global\/"},{"key":"e_1_2_12_3_1","unstructured":"ECDC.Local transmission of clade 1b mpox cases detected in EU\/EEA. Accessed October 25 2025.https:\/\/www.ecdc.europa.eu\/en\/news-events\/local-transmission-clade-1b-mpox-cases-detected-eueea-ecdc-urges-renewed-vigilance"},{"key":"e_1_2_12_4_1","unstructured":"ECDC.Mpox worldwide overview. Accessed January 25 2026.https:\/\/www.ecdc.europa.eu\/en\/mpox-worldwide-overview"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2024.102719"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-025-10512-6"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00273-8"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad482"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-024-02392-0"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13622"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijregi.2023.11.017"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11112701"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad505"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00198-5"},{"key":"e_1_2_12_15_1","unstructured":"European Centre for Disease Prevention and Control\/WHO Regional Office for Europe.Mpox Joint Epidemiological overview.2025."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7215a5"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13542"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.70122"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70283","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.70283","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70283","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T07:51:22Z","timestamp":1790927482000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,5]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1111\/hiv.70283"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70283","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,5]]},"assertion":[{"value":"2026-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}